{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:01:49Z","timestamp":1786122109495,"version":"build-2736575974"},"reference-count":145,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Rep"],"DOI":"10.3892\/or.2026.9166","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T10:10:26Z","timestamp":1784715026000},"page":"1-20","source":"Crossref","is-referenced-by-count":0,"title":["XPO1: From basic research to clinical treatment (Review)"],"prefix":"10.3892","volume":"56","author":[{"given":"Changyan","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Genetics, School of Basic Medicine, Zunyi Medical University, Zunyi, Guizhou 563000, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhu","sequence":"additional","affiliation":[{"name":"Yunnan Key Laboratory of Breast Cancer Precision Medicine, Academy of Biomedical Engineering Kunming Medical University, Kunming, Yunnan 650000, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Genetics, School of Basic Medicine, Zunyi Medical University, Zunyi, Guizhou 563000, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochen","family":"Hou","sequence":"additional","affiliation":[{"name":"Yunnan Key Laboratory of Breast Cancer Precision Medicine, Academy of Biomedical Engineering Kunming Medical University, Kunming, Yunnan 650000, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiumei","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Genetics, School of Basic Medicine, Zunyi Medical University, Zunyi, Guizhou 563000, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youfu","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Genetics, School of Basic Medicine, Zunyi Medical University, Zunyi, Guizhou 563000, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Genetics, School of Basic Medicine, Zunyi Medical University, Zunyi, Guizhou 563000, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"key20260807110114_b1-or-56-3-09166","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"key20260807110114_b2-or-56-3-09166","first-page":"69","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"key20260807110114_b3-or-56-3-09166","first-page":"e70043","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J Clin"},{"key":"key20260807110114_b4-or-56-3-09166","doi-asserted-by":"publisher","first-page":"100962","DOI":"10.1016\/j.drup.2023.100962","article-title":"Current therapy and drug resistance in metastatic castration-resistant prostate cancer","volume":"68","author":"Cai","year":"2023","journal-title":"Drug Resist Updat"},{"key":"key20260807110114_b5-or-56-3-09166","doi-asserted-by":"publisher","first-page":"1125547","DOI":"10.3389\/fphar.2023.1125547","article-title":"Recent progress in targeted therapy for non-small cell lung cancer","volume":"14","author":"Xiao","year":"2023","journal-title":"Front Pharmacol"},{"key":"key20260807110114_b6-or-56-3-09166","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1042\/BST20191055","article-title":"Targeted therapy and drug resistance in triple-negative breast cancer: The EGFR axis","volume":"48","author":"Lev","year":"2020","journal-title":"Biochem Soc Trans"},{"key":"key20260807110114_b7-or-56-3-09166","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41392-023-01649-4","article-title":"Nuclear transport proteins: Structure, function, and disease relevance","volume":"8","author":"Yang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"key20260807110114_b8-or-56-3-09166","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/S0092-8674(00)80370-0","article-title":"Exportin 1 (Crm1p) is an essential nuclear export factor","volume":"90","author":"Stade","year":"1997","journal-title":"Cell"},{"key":"key20260807110114_b9-or-56-3-09166","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41571-020-00442-4","article-title":"The nuclear export protein XPO1 - from biology to targeted therapy","volume":"18","author":"Azmi","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"key20260807110114_b10-or-56-3-09166","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13045-020-00903-4","article-title":"XPO1-dependent nuclear export as a target for cancer therapy","volume":"13","author":"Azizian","year":"2020","journal-title":"J Hematol Oncol"},{"key":"key20260807110114_b11-or-56-3-09166","doi-asserted-by":"publisher","first-page":"646","DOI":"10.7164\/antibiotics.36.646","article-title":"Leptomycins A and B, new antifungal antibiotics. II. Structure elucidation","volume":"36","author":"Hamamoto","year":"1983","journal-title":"J Antibiot (Tokyo)"},{"key":"key20260807110114_b12-or-56-3-09166","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1158\/2159-8290.CD-NB2019-085","article-title":"XPO1 inhibitor approved for multiple myeloma","volume":"9","year":"2019","journal-title":"Cancer Discov"},{"key":"key20260807110114_b13-or-56-3-09166","doi-asserted-by":"publisher","first-page":"a000562","DOI":"10.1101\/cshperspect.a000562","article-title":"The nuclear pore complex and nuclear transport","volume":"2","author":"Wente","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"key20260807110114_b14-or-56-3-09166","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/tra.12174","article-title":"Biological significance of the importin-\u03b2 family-dependent nucleocytoplasmic transport pathways","volume":"15","author":"Kimura","year":"2014","journal-title":"Traffic"},{"key":"key20260807110114_b15-or-56-3-09166","doi-asserted-by":"publisher","first-page":"e23961","DOI":"10.7554\/eLife.23961","article-title":"Nuclear export receptor CRM1 recognizes diverse conformations in nuclear export signals","volume":"6","author":"Fung","year":"2017","journal-title":"Elife"},{"key":"key20260807110114_b16-or-56-3-09166","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/nsmb.1586","article-title":"Structural basis for assembly and disassembly of the CRM1 nuclear export complex","volume":"16","author":"Dong","year":"2009","journal-title":"Nat Struct Mol Biol"},{"key":"key20260807110114_b17-or-56-3-09166","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.pbi.2020.10.006","article-title":"Structural and functional insight into the nuclear pore complex and nuclear transport receptors in plant stress signaling","volume":"58","author":"Li","year":"2020","journal-title":"Curr Opin Plant Biol"},{"key":"key20260807110114_b18-or-56-3-09166","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/S0092-8674(00)80371-2","article-title":"CRM1 is an export receptor for leucine-rich nuclear export signals","volume":"90","author":"Fornerod","year":"1997","journal-title":"Cell"},{"key":"key20260807110114_b19-or-56-3-09166","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.semcancer.2014.03.002","article-title":"Atomic basis of CRM1-cargo recognition, release and inhibition","volume":"27","author":"Fung","year":"2014","journal-title":"Semin Cancer Biol"},{"key":"key20260807110114_b20-or-56-3-09166","doi-asserted-by":"publisher","first-page":"aaf1015","DOI":"10.1126\/science.aaf1015","article-title":"Architecture of the symmetric core of the nuclear pore","volume":"352","author":"Lin","year":"2016","journal-title":"Science"},{"key":"key20260807110114_b21-or-56-3-09166","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1146\/annurev-biochem-062917-011901","article-title":"The structure of the nuclear pore complex (An Update)","volume":"88","author":"Lin","year":"2019","journal-title":"Annu Rev Biochem"},{"key":"key20260807110114_b22-or-56-3-09166","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/ncb1263","article-title":"Crm1 is a mitotic effector of Ran-GTP in somatic cells","volume":"7","author":"Arnaoutov","year":"2005","journal-title":"Nat Cell Biol"},{"key":"key20260807110114_b23-or-56-3-09166","doi-asserted-by":"publisher","first-page":"S178","DOI":"10.1134\/S0006297922140140","article-title":"Targeting XPO1-Dependent nuclear export in cancer","volume":"87","author":"Kim","year":"2022","journal-title":"Biochemistry (Mosc)"},{"key":"key20260807110114_b24-or-56-3-09166","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13045-017-0412-4","article-title":"XPO1 in B cell hematological malignancies: From recurrent somatic mutations to targeted therapy","volume":"10","author":"Camus","year":"2017","journal-title":"J Hematol Oncol"},{"key":"key20260807110114_b25-or-56-3-09166","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3390\/biom15020175","article-title":"XPO1\/Exportin-1 in acute myelogenous leukemia; biology and therapeutic targeting","volume":"15","author":"Bruserud","year":"2025","journal-title":"Biomolecules"},{"key":"key20260807110114_b26-or-56-3-09166","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13045-014-0085-1","article-title":"Nucleo-cytoplasmic transport as a therapeutic target of cancer","volume":"7","author":"Gravina","year":"2014","journal-title":"J Hematol Oncol"},{"key":"key20260807110114_b27-or-56-3-09166","doi-asserted-by":"publisher","first-page":"9305","DOI":"10.1038\/s41598-024-59994-5","article-title":"XPO1 blockade with KPT-330 promotes apoptosis in cutaneous T-cell lymphoma by activating the p53-p21 and p27 pathways","volume":"14","author":"Chakravarti","year":"2024","journal-title":"Sci Rep"},{"key":"key20260807110114_b28-or-56-3-09166","doi-asserted-by":"publisher","first-page":"34567","DOI":"10.18632\/oncotarget.26179","article-title":"XPO1 inhibition by selinexor induces potent cytotoxicity against high grade bladder malignancies","volume":"9","author":"Baek","year":"2018","journal-title":"Oncotarget"},{"key":"key20260807110114_b29-or-56-3-09166","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1158\/1078-0432.CCR-14-1953","article-title":"XPO1\/CRM1 inhibition causes antitumor effects by mitochondrial accumulation of eIF5A","volume":"21","author":"Miyake","year":"2015","journal-title":"Clin Cancer Res"},{"key":"key20260807110114_b30-or-56-3-09166","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1007\/s10238-023-01003-6","article-title":"Prognostic value and therapeutic targeting of XPO1 in chronic lymphocytic leukemia","volume":"23","author":"Xu","year":"2023","journal-title":"Clin Exp Med"},{"key":"key20260807110114_b31-or-56-3-09166","doi-asserted-by":"publisher","first-page":"437","DOI":"10.21037\/jgo.2019.01.17","article-title":"The roles of p53 and XPO1 on colorectal cancer progression in Yemeni patients","volume":"10","author":"Aladhraei","year":"2019","journal-title":"J Gastrointest Oncol"},{"key":"key20260807110114_b32-or-56-3-09166","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/cas.12430","article-title":"Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma","volume":"105","author":"Yoshimura","year":"2014","journal-title":"Cancer Sci"},{"key":"key20260807110114_b33-or-56-3-09166","doi-asserted-by":"publisher","first-page":"101114","DOI":"10.1016\/j.tranon.2021.101114","article-title":"XPO1 inhibition with selinexor synergizes with proteasome inhibition in neuroblastoma by targeting nuclear export of IkB","volume":"14","author":"Galinski","year":"2021","journal-title":"Transl Oncol"},{"key":"key20260807110114_b34-or-56-3-09166","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1128\/MCB.00158-16","article-title":"Leukemia-Associated Nup214 fusion proteins disturb the XPO1-mediated nuclear-cytoplasmic transport pathway and thereby the NF-\u03baB signaling pathway","volume":"36","author":"Saito","year":"2016","journal-title":"Mol Cell Biol"},{"key":"key20260807110114_b35-or-56-3-09166","doi-asserted-by":"publisher","first-page":"101915","DOI":"10.1016\/j.tice.2022.101915","article-title":"Hydrocortisone alleviates sepsis-induced acute kidney injury through HSF-1-mediated transcriptional suppression of XPO1","volume":"79","author":"Jin","year":"2022","journal-title":"Tissue Cell"},{"key":"key20260807110114_b36-or-56-3-09166","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1158\/0008-5472.CAN-23-1992","article-title":"XPO1 enables adaptive regulation of mRNA export required for genotoxic stress tolerance in cancer cells","volume":"84","author":"Marullo","year":"2024","journal-title":"Cancer Res"},{"key":"key20260807110114_b37-or-56-3-09166","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/0008-5472.CAN-23-2966","article-title":"XPO1-Mediated mRNA export of genome maintenance regulators drives chemotherapy resistance in aggressive lymphoma","volume":"84","author":"Knittel","year":"2024","journal-title":"Cancer Res"},{"key":"key20260807110114_b38-or-56-3-09166","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1186\/s12885-025-14257-y","article-title":"Targeting EP300 in diffuse large b-cell lymphoma: Efficacy of A485 and synergistic effects with XPO1 inhibition","volume":"25","author":"Jiang","year":"2025","journal-title":"BMC Cancer"},{"key":"key20260807110114_b39-or-56-3-09166","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/s43018-022-00394-x","article-title":"P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia","volume":"3","author":"Lin","year":"2022","journal-title":"Nat Cancer"},{"key":"key20260807110114_b40-or-56-3-09166","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1158\/1078-0432.CCR-16-1333","article-title":"Inhibition of the nuclear export receptor XPO1 as a therapeutic target for platinum-resistant ovarian cancer","volume":"23","author":"Chen","year":"2017","journal-title":"Clin Cancer Res"},{"key":"key20260807110114_b41-or-56-3-09166","doi-asserted-by":"publisher","first-page":"4826","DOI":"10.3390\/ijms20194826","article-title":"Targeting nuclear exporter protein XPO1\/CRM1 in gastric cancer","volume":"20","author":"Sexton","year":"2019","journal-title":"Int J Mol Sci"},{"key":"key20260807110114_b42-or-56-3-09166","doi-asserted-by":"publisher","first-page":"82144","DOI":"10.18632\/oncotarget.19285","article-title":"Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration","volume":"8","author":"Azmi","year":"2017","journal-title":"Oncotarget"},{"key":"key20260807110114_b43-or-56-3-09166","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1093\/neuonc\/noae280","article-title":"Autophagy modulates glioblastoma cell sensitivity to Selinexor-mediated XPO1 inhibition","volume":"27","author":"Tang","year":"2025","journal-title":"Neuro Oncol"},{"key":"key20260807110114_b44-or-56-3-09166","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1053\/j.gastro.2024.01.025","article-title":"Dual Inhibition of CDK4\/6 and XPO1 induces senescence with acquired vulnerability to CRBN-Based PROTAC drugs","volume":"166","author":"Wang","year":"2024","journal-title":"Gastroenterology"},{"key":"key20260807110114_b45-or-56-3-09166","doi-asserted-by":"publisher","first-page":"4664","DOI":"10.21037\/tcr-21-1646","article-title":"Pan-cancer analysis reveals the roles of XPO1 in predicting prognosis and tumorigenesis","volume":"10","author":"Zhao","year":"2021","journal-title":"Transl Cancer Res"},{"key":"key20260807110114_b46-or-56-3-09166","doi-asserted-by":"publisher","first-page":"1427497","DOI":"10.3389\/or.2024.1427497","article-title":"Novel-and not so novel-inhibitors of the multifunctional CRM1 Protein","volume":"18","author":"Aumann","year":"2024","journal-title":"Oncol Rev"},{"key":"key20260807110114_b47-or-56-3-09166","doi-asserted-by":"publisher","first-page":"56","DOI":"10.2174\/13816128113199990611","article-title":"Understanding XPO1 target networks using systems biology and mathematical modeling","volume":"20","author":"Muqbil","year":"2014","journal-title":"Curr Pharm Des"},{"key":"key20260807110114_b48-or-56-3-09166","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1083\/jcb.200302085","article-title":"Epstein-Barr virus LMP1 blocks p16INK4a-RB pathway by promoting nuclear export of E2F4\/5","volume":"162","author":"Ohtani","year":"2003","journal-title":"J Cell Biol"},{"key":"key20260807110114_b49-or-56-3-09166","doi-asserted-by":"publisher","first-page":"100963","DOI":"10.1016\/j.currproblcancer.2023.100963","article-title":"Selinexor in patients with advanced and recurrent endometrial cancer","volume":"47","author":"Bogani","year":"2023","journal-title":"Curr Probl Cancer"},{"key":"key20260807110114_b50-or-56-3-09166","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.bcp.2017.11.009","article-title":"FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models","volume":"147","author":"Corno","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"key20260807110114_b51-or-56-3-09166","doi-asserted-by":"publisher","first-page":"6099","DOI":"10.1111\/jcmm.13886","article-title":"Inhibition of XPO1 enhances cell death induced by ABT-199 in acute myeloid leukaemia via Mcl-1","volume":"22","author":"Luedtke","year":"2018","journal-title":"J Cell Mol Med"},{"key":"key20260807110114_b52-or-56-3-09166","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41419-019-1627-9","article-title":"XPO1 inhibitor KPT-330 synergizes with Bcl-xL inhibitor to induce cancer cell apoptosis by perturbing rRNA processing and Mcl-1 protein synthesis","volume":"10","author":"Zhu","year":"2019","journal-title":"Cell Death Dis"},{"key":"key20260807110114_b53-or-56-3-09166","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13045-019-0803-9","article-title":"Simultaneous targeting of XPO1 and BCL2 as an effective treatment strategy for double-hit lymphoma","volume":"12","author":"Liu","year":"2019","journal-title":"J Hematol Oncol"},{"key":"key20260807110114_b54-or-56-3-09166","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13046-021-01886-x","article-title":"Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: Evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down-regulation","volume":"40","author":"Zuco","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"key20260807110114_b55-or-56-3-09166","doi-asserted-by":"publisher","first-page":"6","DOI":"10.21037\/sci.2019.02.03","article-title":"The past, present, and future of CRM1\/XPO1 inhibitors","volume":"6","author":"Wang","year":"2019","journal-title":"Stem Cell Investig"},{"key":"key20260807110114_b56-or-56-3-09166","doi-asserted-by":"publisher","first-page":"6816","DOI":"10.3390\/ijms24076816","article-title":"Azacitidine is synergistically lethal with XPO1 inhibitor selinexor in acute myeloid leukemia by targeting XPO1\/eIF4E\/c-MYC signaling","volume":"24","author":"Long","year":"2023","journal-title":"Int J Mol Sci"},{"key":"key20260807110114_b57-or-56-3-09166","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1158\/1535-7163.MCT-15-0798","article-title":"Elevated translation initiation factor eIF4E Is an attractive therapeutic target in multiple myeloma","volume":"15","author":"Li","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"key20260807110114_b58-or-56-3-09166","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1261\/rna.060137.116","article-title":"A biochemical framework for eIF4E-dependent mRNA export and nuclear recycling of the export machinery","volume":"23","author":"Volpon","year":"2017","journal-title":"RNA"},{"key":"key20260807110114_b59-or-56-3-09166","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.cellsig.2018.02.016","article-title":"STAT6 is a cargo of exportin 1: Biological relevance in primary mediastinal B-cell lymphoma","volume":"46","author":"Miloudi","year":"2018","journal-title":"Cell Signal"},{"key":"key20260807110114_b60-or-56-3-09166","doi-asserted-by":"publisher","first-page":"16010","DOI":"10.1038\/sigtrans.2016.10","article-title":"Inhibiting cancer cell hallmark features through nuclear export inhibition","volume":"1","author":"Sun","year":"2016","journal-title":"Signal Transduct Target Ther"},{"key":"key20260807110114_b61-or-56-3-09166","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/leu.2013.115","article-title":"CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: Molecular mechanisms and therapeutic implications","volume":"28","author":"Tai","year":"2014","journal-title":"Leukemia"},{"key":"key20260807110114_b62-or-56-3-09166","doi-asserted-by":"publisher","first-page":"1275329","DOI":"10.3389\/fimmu.2023.1275329","article-title":"Impacting T-cell fitness in multiple myeloma: Potential roles for selinexor and XPO1 inhibitors","volume":"14","author":"Binder","year":"2023","journal-title":"Front Immunol"},{"key":"key20260807110114_b63-or-56-3-09166","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1007\/s40265-019-01188-9","article-title":"Selinexor: First global approval","volume":"79","author":"Syed","year":"2019","journal-title":"Drugs"},{"key":"key20260807110114_b64-or-56-3-09166","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral selinexor-dexamethasone for triple-class refractory multiple myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N Engl J Med"},{"key":"key20260807110114_b65-or-56-3-09166","doi-asserted-by":"publisher","first-page":"e511","DOI":"10.1016\/S2352-3026(20)30120-4","article-title":"Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): A single-arm, multinational, multicentre, open-label, phase 2 trial","volume":"7","author":"Kalakonda","year":"2020","journal-title":"Lancet Haematol"},{"key":"key20260807110114_b66-or-56-3-09166","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.clml.2021.12.016","article-title":"Effect of prior therapy and disease refractoriness on the efficacy and safety of oral selinexor in patients with diffuse large B-cell lymphoma (DLBCL): A Post-hoc Analysis of the SADAL study","volume":"22","author":"Schuster","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"key20260807110114_b67-or-56-3-09166","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","article-title":"Multiple myeloma","volume":"111","author":"Kyle","year":"2008","journal-title":"Blood"},{"key":"key20260807110114_b68-or-56-3-09166","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1186\/s12885-021-08453-9","article-title":"Quality of life analyses in patients with multiple myeloma: Results from the Selinexor (KPT-330) treatment of refractory myeloma (STORM) phase 2b study","volume":"21","author":"Tremblay","year":"2021","journal-title":"BMC Cancer"},{"key":"key20260807110114_b69-or-56-3-09166","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.clml.2022.04.025","article-title":"Matching-adjusted indirect treatment comparison to assess the comparative efficacy of ciltacabtagene autoleucel in CARTITUDE-1 versus belantamab mafodotin in DREAMM-2, selinexor-dexamethasone in STORM part 2, and melphalan flufenamide-dexamethasone in HORIZON for the treatment of patients with triple-class exposed relapsed or refractory multiple myeloma","volume":"22","author":"Weisel","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"key20260807110114_b70-or-56-3-09166","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1080\/14796694.2025.2461393","article-title":"Selinexor plus ruxolitinib in JAK inhibitor treatment-na\u00efve myelofibrosis: SENTRY Phase 3 study design","volume":"21","author":"Mascarenhas","year":"2025","journal-title":"Future Oncol"},{"key":"key20260807110114_b71-or-56-3-09166","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s11523-022-00945-3","article-title":"Selinexor-Bortezomib-Dexamethasone: A review in previously treated multiple myeloma","volume":"18","author":"Syed","year":"2023","journal-title":"Target Oncol"},{"key":"key20260807110114_b72-or-56-3-09166","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1038\/s41375-020-0756-6","article-title":"Integrated safety profile of selinexor in multiple myeloma: Experience from 437 patients enrolled in clinical trials","volume":"34","author":"Gavriatopoulou","year":"2020","journal-title":"Leukemia"},{"key":"key20260807110114_b73-or-56-3-09166","doi-asserted-by":"publisher","first-page":"e975","DOI":"10.1016\/j.clml.2021.07.014","article-title":"Optimal supportive care with selinexor improves outcomes in patients with relapsed\/refractory multiple myeloma","volume":"21","author":"Chari","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"key20260807110114_b74-or-56-3-09166","doi-asserted-by":"publisher","first-page":"6142","DOI":"10.1158\/1078-0432.CCR-15-2885","article-title":"XPO1 inhibition using selinexor synergizes with chemotherapy in acute myeloid leukemia by targeting DNA repair and restoring topoisomerase II\u03b1 to the nucleus","volume":"22","author":"Ranganathan","year":"2016","journal-title":"Clin Cancer Res"},{"key":"key20260807110114_b75-or-56-3-09166","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1038\/s41375-023-01984-z","article-title":"XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression","volume":"37","author":"Fisher","year":"2023","journal-title":"Leukemia"},{"key":"key20260807110114_b76-or-56-3-09166","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1002\/ajh.70266","article-title":"Selinexor and venetoclax combination in patients with relapsed or refractory acute myeloid leukemia","volume":"101","author":"Ball","year":"2026","journal-title":"Am J Hematol"},{"key":"key20260807110114_b77-or-56-3-09166","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.lungcan.2021.08.010","article-title":"Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC)","volume":"160","author":"Nagasaka","year":"2021","journal-title":"Lung Cancer"},{"key":"key20260807110114_b78-or-56-3-09166","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41420-018-0049-2","article-title":"KPT-330 inhibition of chromosome region maintenance 1 is cytotoxic and sensitizes chronic myeloid leukemia to Imatinib","volume":"4","author":"Nie","year":"2018","journal-title":"Cell Death Discov"},{"key":"key20260807110114_b79-or-56-3-09166","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.neo.2019.06.001","article-title":"Overcoming tyrosine kinase inhibitor resistance in transformed cell harboring SEPT9-ABL1 chimeric fusion protein","volume":"21","author":"Kawai","year":"2019","journal-title":"Neoplasia"},{"key":"key20260807110114_b80-or-56-3-09166","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1038\/leu.2016.136","article-title":"Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies","volume":"30","author":"Hing","year":"2016","journal-title":"Leukemia"},{"key":"key20260807110114_b81-or-56-3-09166","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/vde.13280","article-title":"Efficacy of verdinexor for the treatment of na\u00efve canine epitheliotropic cutaneous T-cell lymphoma: An open-label pilot study","volume":"35","author":"Vlodaver","year":"2024","journal-title":"Vet Dermatol"},{"key":"key20260807110114_b82-or-56-3-09166","doi-asserted-by":"publisher","first-page":"E54","DOI":"10.1002\/ajh.26420","article-title":"A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myeloma","volume":"97","author":"Cornell","year":"2022","journal-title":"Am J Hematol"},{"key":"key20260807110114_b83-or-56-3-09166","doi-asserted-by":"publisher","first-page":"675112","DOI":"10.3389\/fmicb.2021.675112","article-title":"The second-generation XPO1 inhibitor eltanexor inhibits human cytomegalovirus (HCMV) replication and promotes type I interferon response","volume":"12","author":"Liao","year":"2021","journal-title":"Front Microbiol"},{"key":"key20260807110114_b84-or-56-3-09166","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1200\/JCO.21.01829","article-title":"Selinexor in advanced, metastatic dedifferentiated liposarcoma: A multinational, randomized, double-blind, placebo-controlled trial","volume":"40","author":"Gounder","year":"2022","journal-title":"J Clin Oncol"},{"key":"key20260807110114_b85-or-56-3-09166","doi-asserted-by":"publisher","first-page":"17588359221081073","DOI":"10.1177\/17588359221081073","article-title":"Overview of systemic therapy options in liposarcoma, with a focus on the activity of selinexor, a selective inhibitor of nuclear export in dedifferentiated liposarcoma","volume":"14","author":"Thirasastr","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"key20260807110114_b86-or-56-3-09166","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1111\/jcmm.17274","article-title":"Venetoclax enhances DNA damage induced by XPO1 inhibitors: A novel mechanism underlying the synergistic antileukaemic effect in acute myeloid leukaemia","volume":"26","author":"Yu","year":"2022","journal-title":"J Cell Mol Med"},{"key":"key20260807110114_b87-or-56-3-09166","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1107\/S2053230X2100203X","article-title":"Crystal structure of human CRM1, covalently modified by 2-mercaptoethanol on Cys528, in complex with RanGTP","volume":"77","author":"Shaikhqasem","year":"2021","journal-title":"Acta Crystallogr F Struct Biol Commun"},{"key":"key20260807110114_b88-or-56-3-09166","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/1873-3468.14018","article-title":"ABCB1\/MDR1\/P-gp employs an ATP-dependent twist-and-squeeze mechanism to export hydrophobic drugs","volume":"595","author":"Kodan","year":"2021","journal-title":"FEBS Lett"},{"key":"key20260807110114_b89-or-56-3-09166","doi-asserted-by":"publisher","first-page":"106499","DOI":"10.1016\/j.leukres.2020.106499","article-title":"Up-regulation of multidrug resistance protein MDR1\/ABCB1 in carfilzomib-resistant multiple myeloma differentially affects efficacy of anti-myeloma drugs","volume":"101","author":"Byrgazov","year":"2021","journal-title":"Leuk Res"},{"key":"key20260807110114_b90-or-56-3-09166","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1101\/gad.343269.120","article-title":"XPO7 is a tumor suppressor regulating p21(CIP1)-dependent senescence","volume":"35","author":"Innes","year":"2021","journal-title":"Genes Dev"},{"key":"key20260807110114_b91-or-56-3-09166","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1038\/s41467-020-15598-x","article-title":"XPO5 promotes primary miRNA processing independently of RanGTP","volume":"11","author":"Wang","year":"2020","journal-title":"Nat Commun"},{"key":"key20260807110114_b92-or-56-3-09166","doi-asserted-by":"publisher","first-page":"e1684","DOI":"10.1002\/ctm2.1684","article-title":"The nuclear export protein exportin-1 in solid malignant tumours: From biology to clinical trials","volume":"14","author":"Lai","year":"2024","journal-title":"Clin Transl Med"},{"key":"key20260807110114_b93-or-56-3-09166","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/nature19771","article-title":"XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer","volume":"538","author":"Kim","year":"2016","journal-title":"Nature"},{"key":"key20260807110114_b94-or-56-3-09166","doi-asserted-by":"publisher","first-page":"1193665","DOI":"10.3389\/fonc.2023.1193665","article-title":"Non-coding RNAs and gastrointestinal cancers prognosis: An umbrella review of systematic reviews and meta-analyses of observational studies","volume":"13","author":"Zha","year":"2023","journal-title":"Front Oncol"},{"key":"key20260807110114_b95-or-56-3-09166","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","article-title":"Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): A randomised, open-label, phase 3 trial","volume":"396","author":"Grosicki","year":"2020","journal-title":"Lancet"},{"key":"key20260807110114_b96-or-56-3-09166","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1182\/blood-2016-11-750174","article-title":"Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma","volume":"129","author":"Kuruvilla","year":"2017","journal-title":"Blood"},{"key":"key20260807110114_b97-or-56-3-09166","doi-asserted-by":"publisher","first-page":"100010","DOI":"10.1016\/j.bneo.2024.100010","article-title":"A novel application of XPO1 inhibition for the treatment of myelofibrosis","volume":"1","author":"Metzger","year":"2024","journal-title":"Blood Neoplasia"},{"key":"key20260807110114_b98-or-56-3-09166","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1182\/blood-2017-08-797886","article-title":"Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia","volume":"131","author":"Chen","year":"2018","journal-title":"Blood"},{"key":"key20260807110114_b99-or-56-3-09166","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/978-1-0716-1720-5_3","article-title":"Target identification of small molecules using large-scale CRISPR-Cas mutagenesis scanning of essential genes","volume":"2377","author":"Kwanten","year":"2022","journal-title":"Methods Mol Biol"},{"key":"key20260807110114_b100-or-56-3-09166","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.chembiol.2024.05.016","article-title":"C646 degrades Exportin-1 to modulate p300 chromatin occupancy and function","volume":"31","author":"Chen","year":"2024","journal-title":"Cell Chem Biol"},{"key":"key20260807110114_b101-or-56-3-09166","doi-asserted-by":"publisher","first-page":"117182","DOI":"10.1016\/j.ejmech.2024.117173","article-title":"Discovery of novel XPO1 PROTAC degraders for the treatment of acute myeloid leukemia","volume":"283","author":"Chen","year":"2025","journal-title":"Eur J Med Chem"},{"key":"key20260807110114_b102-or-56-3-09166","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1093\/procel\/pwaf107","article-title":"Context matters: E3 ligase-ligand pairing strategies for optimized PROTAC performance","volume":"17","author":"Yin","year":"2025","journal-title":"Protein Cell"},{"key":"key20260807110114_b103-or-56-3-09166","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.cell.2019.11.031","article-title":"Proteolysis-targeting chimeras as therapeutics and tools for biological discovery","volume":"181","author":"Burslem","year":"2020","journal-title":"Cell"},{"key":"key20260807110114_b104-or-56-3-09166","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1158\/1078-0432.CCR-19-1728","article-title":"Preclinical assessment with clinical validation of selinexor with gemcitabine and nab-paclitaxel for the treatment of pancreatic ductal adenocarcinoma","volume":"26","author":"Azmi","year":"2020","journal-title":"Clin Cancer Res"},{"key":"key20260807110114_b105-or-56-3-09166","doi-asserted-by":"publisher","first-page":"15383","DOI":"10.1038\/s41598-018-33784-2","article-title":"Dual Inhibition of Bcl-2\/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems","volume":"8","author":"Shang","year":"2018","journal-title":"Sci Rep"},{"key":"key20260807110114_b106-or-56-3-09166","doi-asserted-by":"publisher","first-page":"5340894","DOI":"10.1155\/2018\/5340894","article-title":"Prognostic value of long Noncoding RNAs in patients with gastrointestinal cancer: A systematic review and meta-analysis","volume":"2018","author":"Kang","year":"2018","journal-title":"Dis Markers"},{"key":"key20260807110114_b107-or-56-3-09166","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3389\/fonc.2020.00038","article-title":"PVT1 long Non-coding RNA in gastrointestinal cancer","volume":"10","author":"Mart\u00ednez-Barriocanal","year":"2020","journal-title":"Front Oncol"},{"key":"key20260807110114_b108-or-56-3-09166","doi-asserted-by":"publisher","first-page":"5144","DOI":"10.3390\/ijms25105144","article-title":"Non-Coding RNA as biomarkers and their role in the pathogenesis of gastric cancer-A narrative review","volume":"25","author":"Bakinowska","year":"2024","journal-title":"Int J Mol Sci"},{"key":"key20260807110114_b109-or-56-3-09166","doi-asserted-by":"publisher","first-page":"118499","DOI":"10.1016\/j.ejmech.2025.118499","article-title":"Advances in novel modification strategies for enhancing the tumor tissue specificity of PROTACs","volume":"305","author":"Hu","year":"2026","journal-title":"Eur J Med Chem"},{"key":"key20260807110114_b110-or-56-3-09166","doi-asserted-by":"publisher","first-page":"4142","DOI":"10.1200\/JCO.2015.65.3949","article-title":"First-in-class, first-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors","volume":"34","author":"Abdul Razak","year":"2016","journal-title":"J Clin Oncol"},{"key":"key20260807110114_b111-or-56-3-09166","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1182\/blood-2016-11-750158","article-title":"A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia","volume":"129","author":"Garzon","year":"2017","journal-title":"Blood"},{"key":"key20260807110114_b112-or-56-3-09166","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1634\/theoncologist.2017-0624","article-title":"A phase II trial of selinexor, an oral selective inhibitor of nuclear export compound, in abiraterone- and\/or enzalutamide-refractory metastatic castration-resistant prostate cancer","volume":"23","author":"Wei","year":"2018","journal-title":"Oncologist"},{"key":"key20260807110114_b113-or-56-3-09166","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.ygyno.2019.11.012","article-title":"Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies","volume":"156","author":"Vergote","year":"2020","journal-title":"Gynecol Oncol"},{"key":"key20260807110114_b114-or-56-3-09166","doi-asserted-by":"publisher","first-page":"e566","DOI":"10.1016\/S2352-3026(20)30209-X","article-title":"Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: A single-centre, single-arm, phase 2 trial","volume":"7","author":"Taylor","year":"2020","journal-title":"Lancet Haematol"},{"key":"key20260807110114_b115-or-56-3-09166","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1158\/1078-0432.CCR-21-2225","article-title":"A phase II study of the efficacy and safety of oral selinexor in recurrent glioblastoma","volume":"28","author":"Lassman","year":"2022","journal-title":"Clin Cancer Res"},{"key":"key20260807110114_b116-or-56-3-09166","doi-asserted-by":"publisher","first-page":"5400","DOI":"10.1200\/JCO.22.02906","article-title":"Oral selinexor as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer","volume":"41","author":"Vergote","year":"2023","journal-title":"J Clin Oncol"},{"key":"key20260807110114_b117-or-56-3-09166","doi-asserted-by":"publisher","first-page":"e1513","DOI":"10.1002\/ctm2.1513","article-title":"Molecular analysis of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in KPC pancreatic cancer mouse model","volume":"13","author":"Uddin","year":"2023","journal-title":"Clin Transl Med"},{"key":"key20260807110114_b118-or-56-3-09166","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ygyno.2022.11.004","article-title":"Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer","volume":"168","author":"Westin","year":"2023","journal-title":"Gynecol Oncol"},{"key":"key20260807110114_b119-or-56-3-09166","doi-asserted-by":"publisher","first-page":"9749","DOI":"10.1038\/s41598-017-10325-x","article-title":"Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin","volume":"7","author":"Garg","year":"2017","journal-title":"Sci Rep"},{"key":"key20260807110114_b120-or-56-3-09166","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/1078-0432.CCR-19-2169","article-title":"Phase I clinical trial of selinexor in combination with daunorubicin and cytarabine in previously untreated poor-risk acute myeloid leukemia","volume":"26","author":"Sweet","year":"2020","journal-title":"Clin Cancer Res"},{"key":"key20260807110114_b121-or-56-3-09166","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13045-017-0550-8","article-title":"A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia","volume":"11","author":"Wang","year":"2018","journal-title":"J Hematol Oncol"},{"key":"key20260807110114_b122-or-56-3-09166","doi-asserted-by":"publisher","first-page":"4094","DOI":"10.1200\/JCO.2016.67.5066","article-title":"Phase I study of selinexor, a selective inhibitor of nuclear export, in combination with fludarabine and cytarabine, in pediatric relapsed or refractory acute leukemia","volume":"34","author":"Alexander","year":"2016","journal-title":"J Clin Oncol"},{"key":"key20260807110114_b123-or-56-3-09166","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.ygyno.2017.02.019","article-title":"Uterine leiomyosarcoma: Epidemiology, contemporary treatment strategies and the impact of uterine morcellation","volume":"145","author":"Ricci","year":"2017","journal-title":"Gynecol Oncol"},{"key":"key20260807110114_b124-or-56-3-09166","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/cncr.26333","article-title":"A nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma","volume":"118","author":"Zivanovic","year":"2012","journal-title":"Cancer"},{"key":"key20260807110114_b125-or-56-3-09166","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1002\/cncr.34773","article-title":"Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer","volume":"129","author":"Nelson","year":"2023","journal-title":"Cancer"},{"key":"key20260807110114_b126-or-56-3-09166","doi-asserted-by":"publisher","first-page":"4301","DOI":"10.1158\/1078-0432.CCR-16-2632","article-title":"Selinexor (KPT-330) induces tumor suppression through nuclear sequestration of I\u03baB and downregulation of survivin","volume":"23","author":"Nair","year":"2017","journal-title":"Clin Cancer Res"},{"key":"key20260807110114_b127-or-56-3-09166","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.3324\/haematol.2012.074781","article-title":"Selective inhibitors of nuclear export for the treatment of non-Hodgkin's lymphomas","volume":"98","author":"Azmi","year":"2013","journal-title":"Haematologica"},{"key":"key20260807110114_b128-or-56-3-09166","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1158\/1078-0432.CCR-20-4929","article-title":"Selinexor in Combination with R-CHOP for frontline treatment of Non-Hodgkin lymphoma: results of a phase I study","volume":"27","author":"Seymour","year":"2021","journal-title":"Clin Cancer Res"},{"key":"key20260807110114_b129-or-56-3-09166","doi-asserted-by":"publisher","first-page":"78896","DOI":"10.18632\/oncotarget.12969","article-title":"XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of I\u03baB\u03b1 and overcomes acquired proteasome inhibitor resistance in human multiple myeloma","volume":"7","author":"Turner","year":"2016","journal-title":"Oncotarget"},{"key":"key20260807110114_b130-or-56-3-09166","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1158\/1535-7163.MCT-15-0488","article-title":"Synergistic myeloma cell death via novel intracellular activation of caspase-10-dependent apoptosis by carfilzomib and selinexor","volume":"15","author":"Rosebeck","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"key20260807110114_b131-or-56-3-09166","doi-asserted-by":"publisher","first-page":"78883","DOI":"10.18632\/oncotarget.12428","article-title":"Selinexor, a selective inhibitor of nuclear export (SINE) compound, acts through NF-\u03baB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death","volume":"7","author":"Kashyap","year":"2016","journal-title":"Oncotarget"},{"key":"key20260807110114_b132-or-56-3-09166","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.18632\/oncotarget.28047","article-title":"Selinexor, a selective inhibitor of nuclear export, enhances the anti-tumor activity of olaparib in triple negative breast cancer regardless of BRCA1 mutation status","volume":"12","author":"Marijon","year":"2021","journal-title":"Oncotarget"},{"key":"key20260807110114_b133-or-56-3-09166","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3390\/cancers13020197","article-title":"XPO1 inhibition synergizes with PARP1 inhibition in small cell lung cancer by targeting nuclear transport of FOXO3a","volume":"503","author":"Wang","year":"2021","journal-title":"Cancer Lett"},{"key":"key20260807110114_b134-or-56-3-09166","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/15548627.2023.2252301","article-title":"KPT330 promotes the sensitivity of glioblastoma to olaparib by retaining SQSTM1 in the nucleus and disrupting lysosomal function","volume":"20","author":"Wang","year":"2024","journal-title":"Autophagy"},{"key":"key20260807110114_b135-or-56-3-09166","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1158\/1535-7163.MCT-17-0789-ATR","article-title":"XPO1 inhibitor selinexor overcomes intrinsic ibrutinib resistance in mantle cell lymphoma via nuclear retention of I\u03baB","volume":"17","author":"Ming","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"key20260807110114_b136-or-56-3-09166","doi-asserted-by":"publisher","first-page":"15330338231208608","DOI":"10.1177\/15330338231208608","article-title":"The therapeutic synergy of selinexor and venetoclax in mantle cell lymphoma through induction of DNA damage and perturbation of the DNA damage response","volume":"22","author":"Yuan","year":"2023","journal-title":"Technol Cancer Res Treat"},{"key":"key20260807110114_b137-or-56-3-09166","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med"},{"key":"key20260807110114_b138-or-56-3-09166","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1056\/NEJMoa1315226","article-title":"Ibrutinib resistance in chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"key":"key20260807110114_b139-or-56-3-09166","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11060-020-03580-y","article-title":"Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition","volume":"149","author":"Jim\u00e9nez","year":"2020","journal-title":"J Neurooncol"},{"key":"key20260807110114_b140-or-56-3-09166","doi-asserted-by":"publisher","first-page":"101235","DOI":"10.1016\/j.tranon.2021.101235","article-title":"Identification of nuclear export inhibitor-based combination therapies in preclinical models of triple-negative breast cancer","volume":"14","author":"Rashid","year":"2021","journal-title":"Transl Oncol"},{"key":"key20260807110114_b141-or-56-3-09166","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1182\/blood-2014-10-607648","article-title":"Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia","volume":"125","author":"Ranganathan","year":"2015","journal-title":"Blood"},{"key":"key20260807110114_b142-or-56-3-09166","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.3390\/cancers12061574","article-title":"Cotargeting of XPO1 enhances the antileukemic activity of midostaurin and gilteritinib in acute myeloid leukemia","volume":"12","author":"Brinton","year":"2020","journal-title":"Cancers (Basel)"},{"key":"key20260807110114_b143-or-56-3-09166","doi-asserted-by":"publisher","first-page":"100776","DOI":"10.1016\/j.neo.2022.100776","article-title":"Combining selinexor with alisertib to target the p53 pathway in neuroblastoma","volume":"26","author":"Nguyen","year":"2022","journal-title":"Neoplasia"},{"key":"key20260807110114_b144-or-56-3-09166","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3390\/cancers11040479","article-title":"Combined targeting of estrogen receptor alpha and XPO1 prevent Akt activation, remodel metabolic pathways and induce autophagy to overcome tamoxifen resistance","volume":"11","author":"Kulkoyluoglu-Cotul","year":"2019","journal-title":"Cancers (Basel)"},{"key":"key20260807110114_b145-or-56-3-09166","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1007\/s00277-021-04542-8","article-title":"A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory\/relapsed adult acute myeloid leukemia patients","volume":"100","author":"Mart\u00ednez S\u00e1nchez","year":"2021","journal-title":"Ann Hematol"}],"container-title":["Oncology Reports"],"original-title":[],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T08:01:22Z","timestamp":1786089682000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/or.2026.9166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":145,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,7,22]]}},"URL":"https:\/\/doi.org\/10.3892\/or.2026.9166","relation":{},"ISSN":["1021-335X","1791-2431"],"issn-type":[{"value":"1021-335X","type":"print"},{"value":"1791-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]}}}